Back HIV/AIDS

HIV / AIDS

CROI 2013: HIV Treatment for Children Safe and Highly Effective without Laboratory Monitoring

Children did just as well on antiretroviral therapy (ART) without routine laboratory monitoring of CD4 cell counts or drug side effects as those who received regular monitoring during 4 years of follow-up, researchers from Uganda and Zimbabwe reported at March 6 the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

CROI 2013: New Tenofovir Alafenamide Looks Easier on Kidneys [VIDEO]

A new pro-drug formulation of the widely used nucleotide reverse transcriptase inhibitor analog tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild combination pills) worked as well as the existing formulation, but appears to have less potential for kidney and bone toxicity, according to a presentation Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

CROI 2013: MK-1439, a Novel HIV NNRTI, Shows Promise in Early Clinical Trials

A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated robust antiretroviral activity and good tolerability as monotherapy in a small clinical study, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

CROI 2013: Monthly Injectable and Tenofovir Vaginal Ring Protect Monkeys against Infection

A long-acting injectable integrase inhibitor (GSK1265744) protected male macaque monkeys from rectal infection with an HIV-like virus, while a vaginal ring containing tenofovir prevented infection of female monkeys, researchers reported at the this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

CROI 2013: Very Early Antiretroviral Treatment Limits the Size of HIV Reservoir

Very early antiretroviral treatment may limit the size of the HIV reservoir in adults and children, according to studies presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta. Other research presented at the meeting suggests that too little is known about either the size or the cell types that constitute the HIV reservoir to be confident that early assessments will be a reliable guide to the potential for viral eradication.

alt

CROI 2013: CCR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-inflammatory Effects

Cenicriviroc, which blocks both CCR5 and CCR2 receptors on immune cells, is effective against HIV, better tolerated than current antiretrovirals, and has immunomodulatory activity that may reduce inflammation, according to a presentation yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

CROI 2013: Pipeline Antiretrovirals Promise More Effective and Better Tolerated HIV Treatment

New antiretroviral drugs and treatment strategies are no longer the predominant focus of the annual Conference on Retroviruses and Opportunistic Infections (CROI), but this year's meeting included several presentations on refinements to HIV therapy that offer the prospect of greater efficacy -- especially for people with resistant virus --  fewer side effects, and more convenient administration.

alt